The Journal of Pharmaceutical Investigation announced a January 2027 special issue focused on translational advances in pharmaceutical dosage form development, emphasizing particle engineering, formulation science, manufacturing technologies, and Quality by Design. The call, with submissions due June 30, 2026, targets how lab-scale formulation breakthroughs become manufacturable therapies. The emphasis aligns with a manufacturing reality check: the hardest steps for many candidate drugs involve solubility, stability, and reproducible dosing at scale. By centering particle engineering and dosage form translation, the issue aims to consolidate methods that can de-risk scale-up and regulatory review. For biotech R&D teams, the announcement signals continued editorial focus on bridging formulation research to clinical and manufacturing execution—areas that increasingly determine whether promising molecules become approved products.